ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Aryl Hydrocarbon Hydroxylases/*antagonists & inhibitors ; MAP Kinase Kinase 1/*metabolism ; MAP Kinase Kinase 2/*metabolism ; Proto-Oncogene Protein c-ets-1/*physiology ; Steroid Hydroxylases/*antagonists & inhibitors; Aryl Hydrocarbon Hydroxylases/genetics ; Base Sequence ; Cell Line, Tumor ; DNA ; DNA Methylation ; Humans ; Molecular Sequence Data ; Polymorphism, Single Nucleotide ; Promoter Regions, Genetic ; Steroid Hydroxylases/genetics

EGFR-MEK-ERK signaling pathway has an established role in promoting malignant growth and disease progression in human cancers. Therefore identification of transcriptional targets mediating the oncogenic effects of the EGFR-MEK-ERK pathway would be highly relevant. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently characterized human oncoprotein. CIP2A promotes malignant cell growth and is over expressed at high frequency (40-80%) in most of the human cancer types. However, the mechanisms inducing its expression in cancer still remain largely unexplored. Here we present systematic analysis of contribution of potential gene regulatory mechanisms for high CIP2A expression in cancer. Our data shows that evolutionary conserved CpG islands at the proximal CIP2A promoter are not methylated both in normal and cancer cells. Furthermore, sequencing of the active CIP2A promoter region from altogether seven normal and malignant cell types did not reveal any sequence alterations that would increase CIP2A expression specifically in cancer cells. However, treatment of cancer cells with various signaling pathway inhibitors revealed that CIP2A mRNA expression was sensitive to inhibition of EGFR activity as well as inhibition or activation of MEK-ERK pathway. Moreover, MEK1/2-specific siRNAs decreased CIP2A protein expression. Series of CIP2A promoter-luciferase constructs were created to identify proximal -27 to -107 promoter region responsible for MEK-dependent stimulation of CIP2A expression. Additional mutagenesis and chromatin immunoprecipitation experiments revealed ETS1 as the transcription factor mediating stimulation of CIP2A expression through EGFR-MEK pathway. Thus, ETS1 is probably mediating high CIP2A expression in human cancers with increased EGFR-MEK1/2-ERK pathway activity. These results also suggest that in addition to its established role in invasion and angiogenesis, ETS1 may support malignant cellular growth via regulation of CIP2A expression and protein phosphatase 2A inhibition.

Drug Resist Updat. 2009 Jun;12(3):65-73. (PMID: 19395305)
Oncogene. 1990 Dec;5(12):1761-7. (PMID: 2284095)
Cancer Lett. 2009 Oct 8;283(2):125-34. (PMID: 19217204)
Blood. 2009 Mar 26;113(13):3088-91. (PMID: 19171880)
Mol Med. 2000 Jan;6(1):17-27. (PMID: 10803405)
Ann Surg Oncol. 2011 Mar;18(3):857-65. (PMID: 20842459)
Cell. 2007 Jul 13;130(1):51-62. (PMID: 17632056)
Methods Enzymol. 2003;371:577-96. (PMID: 14712730)
J Cell Physiol. 2006 May;207(2):420-7. (PMID: 16419029)
Expert Opin Ther Targets. 2001 Feb;5(1):87-107. (PMID: 15992169)
Eur J Cancer. 2005 Nov;41(16):2462-78. (PMID: 16213704)
Nucleic Acids Res. 2004 Oct 21;32(18):5693-702. (PMID: 15498926)
Int J Lab Hematol. 2011 Jun;33(3):290-8. (PMID: 21219591)
N Engl J Med. 2010 Aug 26;363(9):809-19. (PMID: 20818844)
EMBO J. 1993 Feb;12(2):479-87. (PMID: 8382609)
Blood. 2008 Nov 15;112(10):4193-201. (PMID: 18716133)
Oncogene. 2002 Jul 25;21(32):5006-15. (PMID: 12118381)
Nat Rev Mol Cell Biol. 2001 Nov;2(11):827-37. (PMID: 11715049)
Trends Mol Med. 2004 Jul;10(7):344-50. (PMID: 15242683)
EMBO J. 2010 Jul 7;29(13):2147-60. (PMID: 20517297)
Nat Rev Cancer. 2010 Feb;10(2):130-7. (PMID: 20094047)
Mol Cancer. 2003 Aug 20;2:29. (PMID: 12971829)
Nature. 2010 Aug 12;466(7308):869-73. (PMID: 20668451)
Clin Cancer Res. 2009 Aug 15;15(16):5092-100. (PMID: 19671842)
Cell Cycle. 2008 Mar 1;7(5):592-6. (PMID: 18256542)
N Engl J Med. 2008 Mar 13;358(11):1160-74. (PMID: 18337605)
Mol Cell Biol. 1996 Feb;16(2):538-47. (PMID: 8552081)
Oncogene. 2007 May 14;26(22):3291-310. (PMID: 17496923)
Proc Natl Acad Sci U S A. 1985 Nov;82(21):7294-8. (PMID: 2997781)
Oncogene. 2010 Nov 25;29(47):6257-66. (PMID: 20729919)
Clin Cancer Res. 2008 Jun 15;14(12):3722-8. (PMID: 18559589)
Cancer Res. 2010 Jan 15;70(2):730-40. (PMID: 20068146)
Oncogene. 2005 Aug 11;24(34):5384-8. (PMID: 15940256)
Mol Cancer Ther. 2009 Sep;8(9):2526-36. (PMID: 19755509)
Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931)
J Natl Cancer Inst. 2009 Jun 3;101(11):793-805. (PMID: 19470954)
PLoS Genet. 2009 Dec;5(12):e1000778. (PMID: 20019798)
Cancer Res. 1998 Dec 1;58(23):5321-5. (PMID: 9850057)
EMBO Rep. 2007 Sep;8(9):871-8. (PMID: 17721441)

08-0614 United Kingdom AICR_ Worldwide Cancer Research

0 (ETS1 protein, human)
0 (Proto-Oncogene Protein c-ets-1)
9007-49-2 (DNA)
EC 1.14.- (Steroid Hydroxylases)
EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
EC 1.14.14.1 (steroid hormone 7-alpha-hydroxylase)
EC 2.7.1.- (MAP2K2 protein, human)
EC 2.7.12.2 (MAP Kinase Kinase 1)
EC 2.7.12.2 (MAP Kinase Kinase 2)

Date Created: 20110330 Date Completed: 20110802 Latest Revision: 20211020

20250114

PMC3062549

10.1371/journal.pone.0017979

21445343